Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.

MLA

Ratziu, Vlad, et al. “Artificial Intelligence Scoring of Liver Biopsies in a Phase II Trial of Semaglutide in Nonalcoholic Steatohepatitis.” Hepatology (02709139), vol. 80, no. 1, July 2024, pp. 173–85. EBSCOhost, https://doi.org/10.1097/HEP.0000000000000723.

APA

Ratziu, V., Francque, S., Behling, C. A., Cejvanovic, V., Cortez-Pinto, H., Iyer, J. S., Krarup, N., Le, Q., Sejling, A.-S., Tiniakos, D., & Harrison, S. A. (2024). Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology (02709139), 80(1), 173–185. https://doi.org/10.1097/HEP.0000000000000723

Chicago

Ratziu, Vlad, Sven Francque, Cynthia A. Behling, Vanja Cejvanovic, Helena Cortez-Pinto, Janani S. Iyer, Niels Krarup, et al. 2024. “Artificial Intelligence Scoring of Liver Biopsies in a Phase II Trial of Semaglutide in Nonalcoholic Steatohepatitis.” Hepatology (02709139) 80 (1): 173–85. doi:10.1097/HEP.0000000000000723.